Jiangsu Sihuan Bioengineering Co., Ltd

Shenzhen Stock Exchange:000518.SZ

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

China

Market Cap

USD 366.53 M

Share Price

USD 0.36

Avg Daily Volume

31,916,724

Change (1 day)

-2.83%

Change (1 year)

30.66%

Change (YTD)

2.74%

Jiangsu Sihuan Bioengineering Co., Ltd EBITDA for the year ending December 31, 2024: USD -12.34 M

Jiangsu Sihuan Bioengineering Co., Ltd EBITDA is USD -12.34 M for the year ending December 31, 2024, a 59.32% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Jiangsu Sihuan Bioengineering Co., Ltd EBITDA for the year ending December 31, 2023 was USD -7.75 M, a 89.98% change year over year.
Jiangsu Sihuan Bioengineering Co., Ltd EBITDA for the year ending December 31, 2022 was USD -4.08 M, a 128.38% change year over year.
Jiangsu Sihuan Bioengineering Co., Ltd EBITDA for the year ending December 31, 2021 was USD -1.79 M, a -120.95% change year over year.
Jiangsu Sihuan Bioengineering Co., Ltd EBITDA for the year ending December 31, 2020 was USD 8.52 M, a 18.06% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shenzhen Stock Exchange: 000518.SZ

Jiangsu Sihuan Bioengineering Co., Ltd

CEO	Mr. Yu Guo
IPO Date	Sept. 8, 1993
Location	China
Headquarters	No. 7 Binjiang East Road
Employees	282
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.